Chemokine (C-C Motif) Ligand 2 (CCL2) in Sera of Patients with Type 1 Diabetes and Diabetic Complications
dc.contributor.author | Guan, Ruili | |
dc.contributor.author | Purohit, Sharad | |
dc.contributor.author | Wang, Hongjie | |
dc.contributor.author | Bode, Bruce | |
dc.contributor.author | Reed, John Chip | |
dc.contributor.author | Steed, R. Dennis | |
dc.contributor.author | Anderson, Stephen W. | |
dc.contributor.author | Steed, Leigh | |
dc.contributor.author | Hopkins, Diane | |
dc.contributor.author | Xia, Chun | |
dc.contributor.author | She, Jin-Xiong | |
dc.date.accessioned | 2012-10-26T16:26:58Z | |
dc.date.available | 2012-10-26T16:26:58Z | |
dc.date.issued | 2011-04-12 | en_US |
dc.identifier.citation | PLoS One. 2011 Apr 12; 6(4):e17822 | en_US |
dc.identifier.issn | 1932-6203 | en_US |
dc.identifier.pmid | 21532752 | en_US |
dc.identifier.doi | 10.1371/journal.pone.0017822 | en_US |
dc.identifier.uri | http://hdl.handle.net/10675.2/648 | |
dc.description.abstract | Background: Chemokine (C-C motif) ligand 2 (CCL2), commonly known as monocyte chemoattractant protein-1 (MCP-1), has been implicated in the pathogenesis of many diseases characterized by monocytic infiltration. However, limited data have been reported on MCP-1 in type 1 diabetes (T1D) and the findings are inconclusive and inconsistent. | |
dc.description.abstract | Methods: In this study, MCP-1 was measured in the sera from 2,472 T1D patients and 2,654 healthy controls using a Luminex assay. The rs1024611 SNP in the promoter region of MCP-1 was genotyped for a subset of subjects (1764 T1D patients and 1323 controls) using the TaqMan-assay. | |
dc.description.abstract | Results: Subject age, sex or genotypes of MCP-1 rs1024611SNP did not have a major impact on serum MCP-1 levels in either healthy controls or patients. While hemoglobin A1c levels did not have a major influence on serum MCP-1 levels, the mean serum MCP-1 levels are significantly higher in patients with multiple complications (mean=242 ng/ml) compared to patients without any complications (mean=201 ng/ml) (p=3.5x10^-6). Furthermore, mean serum MCP-1 is higher in controls (mean=261 ng/ml) than T1D patients (mean=208 ng/ml) (p<10^-23). More importantly, the frequency of subjects with extremely high levels (>99th percentile of patients or 955 ng/ml) of serum MCP-1 is significantly lower in the T1D group compared to the control group (odds ratio=0.11, p<10^-33). | |
dc.description.abstract | Conclusion: MCP-1 may have a dual role in T1D and its complications. While very high levels of serum MCP-1 may be protective against the development of T1D, complications are associated with higher serum MCP-1 levels within the T1D group. | |
dc.rights | Guan et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. | en_US |
dc.subject | Research Article | en_US |
dc.subject | Biology | en_US |
dc.subject | Biochemistry | en_US |
dc.subject | Proteins | en_US |
dc.subject | Plasma Proteins | en_US |
dc.subject | Medicine | en_US |
dc.subject | Clinical Immunology | en_US |
dc.subject | Immune System | en_US |
dc.subject | Cytokines | en_US |
dc.subject | Autoimmune Diseases | en_US |
dc.subject | Genetics of the Immune System | en_US |
dc.subject | Endocrinology | en_US |
dc.subject | Diabetic Endocrinology | en_US |
dc.subject | Diabetes Mellitus Type 1 | en_US |
dc.title | Chemokine (C-C Motif) Ligand 2 (CCL2) in Sera of Patients with Type 1 Diabetes and Diabetic Complications | en_US |
dc.type | Article | en_US |
dc.identifier.pmcid | PMC3075244 | en_US |
dc.contributor.corporatename | Center for Biotechnology and Genomic Medicine | |
dc.contributor.corporatename | Department of Pathology | |
refterms.dateFOA | 2019-04-10T00:24:13Z | |
html.description.abstract | Background: Chemokine (C-C motif) ligand 2 (CCL2), commonly known as monocyte chemoattractant protein-1 (MCP-1), has been implicated in the pathogenesis of many diseases characterized by monocytic infiltration. However, limited data have been reported on MCP-1 in type 1 diabetes (T1D) and the findings are inconclusive and inconsistent. | |
html.description.abstract | Methods: In this study, MCP-1 was measured in the sera from 2,472 T1D patients and 2,654 healthy controls using a Luminex assay. The rs1024611 SNP in the promoter region of MCP-1 was genotyped for a subset of subjects (1764 T1D patients and 1323 controls) using the TaqMan-assay. | |
html.description.abstract | Results: Subject age, sex or genotypes of MCP-1 rs1024611SNP did not have a major impact on serum MCP-1 levels in either healthy controls or patients. While hemoglobin A1c levels did not have a major influence on serum MCP-1 levels, the mean serum MCP-1 levels are significantly higher in patients with multiple complications (mean=242 ng/ml) compared to patients without any complications (mean=201 ng/ml) (p=3.5x10^-6). Furthermore, mean serum MCP-1 is higher in controls (mean=261 ng/ml) than T1D patients (mean=208 ng/ml) (p<10^-23). More importantly, the frequency of subjects with extremely high levels (>99th percentile of patients or 955 ng/ml) of serum MCP-1 is significantly lower in the T1D group compared to the control group (odds ratio=0.11, p<10^-33). | |
html.description.abstract | Conclusion: MCP-1 may have a dual role in T1D and its complications. While very high levels of serum MCP-1 may be protective against the development of T1D, complications are associated with higher serum MCP-1 levels within the T1D group. |